Dare Bioscience, Inc.
Raising nowPublicBiotech · San Diego, CA
Daré Bioscience develops women's health products spanning contraception, menopause, pelvic pain, fertility, sexual and vaginal health, and infectious disease. It pursues both FDA approval and faster access through Section 503B compounding; its first product, DARE to PLAY, is a topical sildenafil cream for female sexual arousal.
This company has an open fundraising round.
Financials
FY2012–FY2025 · from SEC filings · hover any figure for its sourceChart shows the most recent 8 fiscal years; 6 earlier years are in the table below.
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Jun 30, 2026| Class | Outstanding | Votes / share | Converts | As converted | Votes | Liquidation | Last price |
|---|---|---|---|---|---|---|---|
| Common stock | 15,169,502 | — | — | 99.1% | 100.0% | paid 2nd | $5.00Jan 2026 |
| Series A Preferred Stockpreferred(as of Mar 30, 2026) | 65,640 | none | 2 × common stock | 0.86% | 0% | — | — |
| Total | 15,235,142 | 15,300,782 as converted | 100% | 100% |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- William H. Rastetter, Ph.D.6K (0.15%) Mar 2021 → 21K (0.15%) Nov 2025 → 21K (0.15%) Dec 2025
- Lisa Walters-Hoffert49K (1.24%) Mar 2021 → 37K (0.26%) Nov 2025
- MarDee Haring-Layton68K (0.48%) Nov 2025 → 70K (0.48%) Dec 2025
- Sabrina Martucci Johnson110K (2.8%) Mar 2021 → 328K (2.3%) Nov 2025 → 334K (2.3%) Dec 2025
- Susan L. Kelley, M.D.5K (0.13%) Mar 2021 → 20K (0.14%) Nov 2025 → 20K (0.14%) Dec 2025
- Jessica D. Grossman, M.D.4K (0.11%) Mar 2021 → 20K (0.14%) Nov 2025
Principal holders% as the filing states it, Dec 29, 2025
- Law Custodial Inc.1,409,167 common stock9.9%of company
- Sabrina Martucci Johnson334,144 common stock2.3%of company
- Lisa Walters-Hoffert36,959 common stock—of votes
- MarDee Haring-Layton69,715 common stock—of votes
- Robin J. Steele40,530 common stock—of votes
- Susan L. Kelley, M.D.20,438 common stock—of votes
- Gregory W. Matz19,874 common stock—of votes
- William H. Rastetter, Ph.D.21,296 common stock—of votes
- Jessica D. Grossman, M.D.19,832 common stock—of votes
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. “As converted” counts each class in the shares it converts into. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
2 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 77 filings on EDGAR- Form DAug 20, 20260001493152-26-039295EDGAR
- Form 253G2Aug 19, 20260001493152-26-039244EDGAR
- Form 10-QAug 13, 20260001401914-26-000043EDGAR
- Form 253G2Jul 17, 20260001401914-26-000041EDGAR
- Form 253G2May 15, 20260001401914-26-000028EDGAR
- Form 10-QMay 14, 20260001401914-26-000026EDGAR
- Form QUALIFApr 1, 20269999999994-26-000077EDGAR
- Form 253G2Mar 30, 20260001493152-26-013351EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.